DNDN
RT @BiotechStockRsr: No adverse impact on $DNDN Provenge from the $AMGN denosumab news, by the way. Products are complimentary .
DNDN
No adverse impact on $DNDN Provenge from the $AMGN denosumab news, by the way. Products are complimentary and not competitive.
DNDN
@DogDayAftern00n $dndn is the only drug that will help, FDA at it's best!
DNDN
@cacacemike What's right to you and me ain't always right to the statistical lunatics at the FDA $DNDN
DNDN
$dndn approval a must! It's only right!
DNDN
Update on $MDVN $JNJ $DNDN prostate cancer drugs http://bit.ly/ccucjw
DNDN
@DogDayAftern00n $bcrx $dndn $appl $dndn $seed I want my mommy how can you have any pudding if you don't eat your meat!"
"You! Yes
DNDN
@bearcharts $DNDN Read that article. Many flaws in it. SeekingAlpha sucks anyways. Glad you got calls - smart man.
DNDN
Got completely stopped out of $DNDN today. Unfortunately, I wish I got stopped on some other ones too. :( $YGE $AMZN $GOOG $TNA $TYH
DNDN
@bearcharts FYI I think you're nuts for holding a stock like $DNDN overnight. FDA approval could come at any time.
DNDN
long $DNDN @ 29.46, might sell Feb 30 or 31 calls later
DNDN
sold balance $DNDN calls +.10 refust to let it turn into loser
DNDN
sold half $DNDN calls +.32 just in case it gets dragged further by market
DNDN
$$ Some charts to keep an eye on tomorrow http://bit.ly/cv6FRA $DNDN, $SPR, $JLL
DNDN
Third time $DNDN closed at or within a penny of 30.42. Putting a hard stop for 1/2 at 30, 1/4 at 29.50, and 1/4 at 5% stop-loss.
DNDN
$DNDN, $MCD just name a few, made new high, they made into hint list two days ago. All big moves start with a hint day.http://bit.ly/agb9MJ
DNDN
3 fantastic days for $DNDN. Please do yourself a favor & investigate Dendreon, then invest your money. Get in now, huge upside still ahe
DNDN
RT @SellPuts: $DNDN is one if not the most volatile stocks out there.. she will take u out back and whip you <- Yup I got marks on my bac
DNDN
@desolacapital $DNDN is one if not the most volatile stocks out there.. maybe $RMBS is a second.. she will take u out back and whip you
DNDN
Someone is hiding their offer size at that 30.50 level in $DNDN, shook me out...
DNDN
$DNDN chart .. great 3 day trend. http://chart.ly/5x3a39 .. nice trade @alphatrends
DNDN
all time closing high in $DNDN 30.36
DNDN
@alphatrends nice ... You own $DNDN ...always have
DNDN
doing very little today, $DNDN holds up very well and staying above 30 could set it up for bigger breakout, i'm long calls
DNDN
$DNDN announced webcast presentation @12th Bio CEO and investor conference. Tues 2/9 @ 2pm $30!!
Dendreon Corp. - DNDN Insiders
No Insiders
We have no insiders for Dendreon right now.
Know someone who is an insider on Dendreon Corp.?
Let us know.
Dendreon Corp. - DNDN information
Dendreon Corporation, a biotechnology company, engages in the discovery, development, and commercialization of novel therapeutics that harness the immune system to fight cancer. The company’s product portfolio includes active cellular immunotherapy, monoclonal antibodies, and small molecules products candidates to treat a range of cancers. Its product candidate include Provenge (sipuleucel-T), an active cellular immunotherapy that has completed 2 Phase III clinical trials for the treatment of asymptomatic, metastatic, and androgen-independent prostate cancer; Neuvenge (lapuleucel-T), which has completed phase 1 clinical trials for the treatment of breast, ovarian, and colon cancers. The comp......
www.dendreon.com
484 Employees
Founded in 1992
DENDREON CORP (DNDN:NASDAQ GM)
LAST $40.94 USD
CHANGE TODAY +0.36 0.89%
VOLUME 2.0M
As of 1:45 PM 09/3/10 All times are local (Market data is delayed by at least 15 minutes).
Snapshot of DENDREON CORP (DNDN)
|
OPEN
$41.00
|
PREVIOUS CLOSE
$40.58
|
|
|
DAY HIGH
$41.58
|
DAY LOW
$40.33
|
|
|
52 WEEK HIGH
04/30/10 - $57.67
|
52 WEEK LOW
09/3/09 - $22.83
|
|
|
MARKET CAP
5.9B
|
AVERAGE VOLUME 10 D
3.0M
|
|
|
EPS TTM
$-1.49
|
SHARES OUTSTANDING
144.0M
|
|
|
DNDN Does Not Pay Dividends
|
P/E TTM
--
|
|
| K = Thousands M = Millions B = Billions | ||
related news
Oncothyreon names Julie Eastland as CFO
AP Digital - 08/31/2010 3:44 PM ET
Key developments for DENDREON CORP (DNDN)
Dendreon Corp. expected to report Q3 2010 results on November 3, 2010. This event was calculated by Capital IQ (Created on August 5, 2010).
08/5/2010
Dendreon Corp. expected to report Q3 2010 results on November 3, 2010. This event was calculated by Capital IQ (Created on August 5, 2010).
Dendreon Corp. Reports Earnings Results for Second Quarter 2010
08/3/2010
Dendreon Corp. reported earnings results for second quarter 2010. For the period the company reported Provenge sales of $2.8 million. The company reported a net loss of $142.6 million, or $1.04 a share.
Dendreon Corp. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2010
08/3/2010
Dendreon Corp. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2010. For the quarter, the company reported revenue was $2,810,000 against $25,000 for the same period a year earlier. Loss from operations was $68,322,000 against $20,904,000 for the same period a year earlier. Net loss was $142,616,000 or $1.04 per diluted share against $126,717,000 or $1.20 per diluted share for the same period a year earlier For the six months, the company reported revenue was $2,831,000 against $55,000 for the same period a year earlier. Loss from operations was $125,933,000 against $37,889,000 for the same period a year earlier. Net loss was $268,346,000 or $2.00 per diluted share against $142,101,000 or $1.41 per diluted share for the same period a year earlier.
DNDN Competitors
| Company | Last | Change |
| Generex Biotechnology Corp | $0.41 USD | +0.0038 |
| MannKind Corp | $5.75 USD | -0.0001 |
| Market data is delayed at least 15 minutes. | ||
Industry Analysis
| Valuation | DNDN | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 1,927.2x |
|
| Price/Book | 9.3x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 1,837.5x |
|
|
DNDN |
||
|
DNDN transactions
| Type Date |
Target | |
| No transactions in the last 6 months. | ||
Dendreon Corp. - DNDN news
Biotech Stocks: Orexigen soars on Takeda deal; drug indexes rise
2010-09-03 07:06:27
Keywords: Markets|U.S. & Canada, OREX, Orexigen Therapeutics Inc, VVUS, Vivus Inc, ARNA, Arena Pharmaceuticals Inc , DNDN, Dendreon Corp, DRG, ARCA PHARM INDEX, BTK, NYSARC BIOTECH
Quote: The agency is expected to decide whether to approve Vivus Inc.'s/quotes/comstock/15*!vvus/quotes/nls/vvus(VVUS6.34,+0.62,+10.84%) Qnexa and Arena Pharmaceuticals Inc.'s/quotes/comstock/15*!arna/quotes/nls/arna(ARNA6.74,+0.17,+2.59%)See story on new diet pills.Shares of Vivus jumped 9%, while Arena shares rose 2%.Dendreon Corp./quotes/comstock/15*!dndn/quotes/nls/dndn(DNDN40.58,+2.34,+6.12%) shares rallied for the second day, climbing 6%.According to reports late Tuesday, Medicare and Medicaid of...Read article
Biotech Stocks: Orexigen soars on Takeda deal; Vivus gains
2010-09-03 07:06:26
Keywords: Markets|U.S. & Canada, OREX, Orexigen Therapeutics Inc, VVUS, Vivus Inc, ARNA, Arena Pharmaceuticals Inc , DNDN, Dendreon Corp, DRG, ARCA PHARM INDEX, BTK, NYSARC BIOTECH
Quote: The agency is expected to decide whether to approve Vivus Inc.'s/quotes/comstock/15*!vvus/quotes/nls/vvus(VVUS6.34,+0.62,+10.84%) Qnexa and Arena Pharmaceuticals Inc.'s/quotes/comstock/15*!arna/quotes/nls/arna(ARNA6.74,+0.17,+2.59%)See story on new diet pills.Shares of Vivus jumped 9%, while Arena shares rose 2%.Dendreon Corp./quotes/comstock/15*!dndn/quotes/nls/dndn(DNDN40.58,+2.34,+6.12%) shares rallied for the second day, climbing 6%.According to reports late Tuesday, Medicare and Medicaid of...Read article
Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
2010-09-02 08:24:48
Keywords: Dendreon Announces Webcast Presentations at Upcoming Investor Conferences, dndn
Quote: ETThe presentations will be audio webcast live and available for replay from Dendreon's website, www.dendreon.com. Â Dendreon Corporation is a biotechnology company targeting cancer and transforming lives through the discovery, development, commercialization and manufacturing of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response in a...Read article
Dendreon Gets Date for Medicare Meeting
2010-09-01 06:31:51
Keywords: Financial, News, Stock, Market, Headlines, Investments, Quotes, Trading, TheStreet.com, Adam Feuerstein ,Drugs
Quote: 17 to discuss the use of Dendreon's(DNDN) prostate cancer vaccine Provenge.web site of the Centers for Medicare and Medicaid Services (CMS)."The Centers for Medicare and Medicaid Services (CMS) has called this meeting to consider the currently available evidence regarding the impact of labeled and unlabeled use of autologous cellular immunotherapy treatment on health outcomes of patients with metastatic prostate cancer," the agency's announcement stated.assessment to determine a national coverag...Read article
Medicare Meeting A Good Sign For Dendreon
2010-09-01 06:31:50
Quote: The Centers for Medicare and Medicaid Services have scheduled a meeting on November 17 to discuss the proper use of Dendreon’s prostate cancer treatment Provenge, a first-of-its kind cell therapy meant to train the immune system to attack prostate cancer cells. The speed with which the meeting was scheduled and the topics covered are a positive for the company.
Dendreon investors were spooked in July when Medicare began a 12-month process to evaluate how and for whom Provenge should be cov...Read article
UPDATE - US Medicare agency sets meeting on Dendreon vaccine
2010-09-01 06:31:50
Keywords: Health / Medicine,Biotechnology / Pharmaceuticals,United States,US Government News,Regulations / Standards,Biotechnology / Medical Research,Biotechnology / Medical Research,Healthcare,Insurance,Financials,General News,Society / Science / Nature,Politics /
Quote: 17
advisory panel meeting on Tuesday to review data on Dendreon
Corp's (DNDN.O) novel treatment for advanced prostate cancer. The Centers for Medicare & Medicaid Services (CMS) said in
June that it was considering a nationwide coverage policy for
Provenge, a vaccine that stimulates the body's immune system to
fight prostate cancer. Nationwide Medicare coverage can help boost a product's
success, while a denial can sharply dent sales. Medicare is the
federal health insurance that covers about...Read article
Dendreon: Medicare Coverage Fears Allayed
2010-09-01 06:31:48
Keywords: Financial, News, Stock, Market, Headlines, Investments, Quotes, Trading, TheStreet.com, Adam Feuerstein ,Drugs
Quote: 17 to discuss the use of Dendreon'sDNDN) prostate cancer vaccine Provenge.web site of the Centers for Medicare and Medicaid Services (CMS)."The Centers for Medicare and Medicaid Services (CMS) has called this meeting to consider the currently available evidence regarding the impact of labeled and unlabeled use of autologous cellular immunotherapy treatment on health outcomes of patients with metastatic prostate cancer," the agency's announcement stated.The fact that CMS is focusing its attention...Read article
DENDREON CORP Files SEC form 8-K, Other Events
2010-08-27 05:14:10
Quote: Urdal, Ph.D., Senior Vice President and Chief Scientific Officer for
Dendreon Corporation (the "Company"), and a member of the Company's board of
directors, adopted a pre-arranged trading plan (the "Plan") designed to comply
with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, and the
Company's policy regarding insider stock trading transactions. Under Rule
10b5-1, directors, officers and other persons who are not at that time in
possession of material non-...Read article
Analyst Research on Dendreon and Amylin Pharmaceuticals - Biotech Stocks Looking Averagely Attractive
2010-08-20 01:47:26
Keywords: Analyst Research on Dendreon and Amylin Pharmaceuticals - Biotech Stocks Looking Averagely Attractive, amln,dndn
Quote: JOHANNESBURG, SOUTH AFRICA--(Marketwire - 08/19/10) - www.stockcall.com/ offers investors comprehensive research on the biotechnology industry and has completed analytical research on Dendreon Corp. DNDNNews) and Amylin Pharmaceuticals Inc. AMLNNewswww.stockcall.com/ to have free access to these researches.https://stockcall.com/development/stockcall/page.php?name=register.html to have free access to our reports on the biotechnology industry.www.stockcall.com/https://stockcall.com/development/st...Read article
Wall to Wall Street Coverage: Upgrades and Downgrades
2010-08-16 08:50:21
Keywords: Wall to Wall Street Coverage: Upgrades and Downgrades, amgn,chk,coco,dndn,vmw
Quote: DendreonDNDN) and GileadGILD) are both Buys while AmgenAMGN) and BiogenBIIBWhy Biotech Investing Is Not for the Meek.ComstockCRK): Global Hunter Securities rolls out Buy rated coverage of Comstock.UpgradesChesapeake EnergyCHK): The stock gets an Outperform-from-Market perform boost by BMO Capital, which has a price objective of $30.Cavium NetworksCAVM): CAVM is now a Strong Buy from Buy at with a $37 target price at Needham.Provident FinancialPFS): Janney Montgomery Scott moves Provident Financi...Read article
Pharma Stories You May Have Missed
2010-08-12 06:30:51
Quote: Here are a few posts that you may have missed about the sales potential for the first cancer vaccine, why pharmaceutical giants are failing at their attempts to develop cancer drugs, and the race to market new pills to fight the hepatitis C virus.
Dendreon’s Magic Numbers: “Whenever you see a bigparadigm shift and a disruptive technology that changes the way thingsare done, it takes some people a little while to get over that hump,” says chief executive Mitchell Gold. Here are ...Read article
UPDATE - US FDA objects to Dendreon promotions for Provenge
2010-08-09 09:33:13
Keywords: Pharmaceuticals (sub-industry),United States of America,Health and medicine,Washington / US Government News,Regulation and enforcement,Biotechnology,Healthcare,General News,Nature Society and Science,Politics International Affairs and Law,Domestic Politic
Quote: Fri Aug 6, 2010 5:34pm EDT
* FDA letter: Company overstated benefits, minimized risks * Dendreon shares end higher(Adds company comment, details on product; updates shares)WASHINGTON Aug 6 (Reuters) - Dendreon Corp (DNDN.O)
exaggerated the benefits of its novel prostate cancer vaccine
and downplayed risks in some sales materials for the product,
U.S. regulators said in a letter released on Friday. "These promotional materials are false or misleading
because they omit and minimize the risks and ...Read article
Biotech Stocks: Depomed, Dendreon lead drug stocks higher
2010-08-05 05:46:58
Keywords: Markets|U.S. & Canada, DEPO, DepoMed Inc, PFE, Pfizer Inc, DNDN, Dendreon Corp, AKRX, Akorn Inc, DRG, ARCA PHARM INDEX, BTK, NYSARC BIOTECH
Quote: States fight new federal health-care lawAs polls show growing voter discontent, states are lining up challenges to new federal health-care legislation.Video courtesy of Fox News.Pfizer shares/quotes/comstock/13*!pfe/quotes/nls/pfe(PFE16.44,+0.28,+1.73%)Read more about Pfizer's earnings.Dendreon Corp. shares/quotes/comstock/15*!dndn/quotes/nls/dndn(DNDN39.78,+5.95,+17.59%) were also on a roll, up 15% to $39.15.Late Tuesday, Dendreon reported that sales of its recently approved prostate-cancer tre...Read article
US STOCKS-Wall St advances on data, Priceline helps
2010-08-05 05:46:57
Keywords: United States of America,Equities,Market Reports,Leisure and recreation,Commercial services and supplies (industry group),Industrial machinery,Machinery,Pharmaceuticals (sub-industry),Speciality retail,Retailing,Discount retail,Internet software and servi
Quote: The Nasdaq also got a lift from Dendreon Corp (DNDN.O), up
15.1 percent at $38.90 on details of the launch of the
company's new prostate cancer vaccine and news that it was
piling up favorable reimbursement notices from health plans.
[ID:nN04243988]. Barnes & Noble (BKS.N) shot up 20.6 percent to $15.48
after the No. 1 U.S bookstore chain put itself up for sale as
business suffers in the high-stakes battle for a leading role
in the digital books market. Shares of industry giant Amazon.com (A...Read article
Q2 2010 Dendreon Earnings Release - Time Not Supplied
2010-08-04 07:42:52
Quote: HortonDHIBefore Market OpenListenDean FoodsDFBefore Market OpenListenDendreonDNDNAfter Market CloseDenny's CorporationDENNAfter Market CloseListenDeutsche Post AGDPW.DE01:00 am ETDexCom, Inc.DXCMAfter Market CloseListenDIGITALGLOBE INCDGIAfter Market CloseListenDiscovery Communications IncDISCK07:00 am ETListenDole Food Company, Inc.DOLEAfter Market CloseListenDollar Thrifty Automotive GroupDTGBefore Market OpenListenDouglas Emmett IncDEIAfter Market CloseListendrugstore.comDSCMAfter Market Clos...Read article
Dendreon Reports Second Quarter 2010 Financial Results
2010-08-04 07:42:50
Keywords: Dendreon Reports Second Quarter 2010 Financial Results, dndn
Quote: Â In addition, we are on track with the expansion of all of our manufacturing facilities in order to provide PROVENGE to more patients in 2011."Dendreon's total operating expenses for the second quarter of 2010 were $68.4 million compared to $20.9 million in 2009. Dendreon's total operating expenses for the six months ended June 30, 2010 were $126.1 million compared to $37.9 million for the same period in 2009. The net loss for the quarter ended June 30, 2010 was $142.6 million, or $1.04 per s...Read article
Dendreon reports $143M loss in Q2
2010-08-04 07:42:49
Quote: Dendreon Corp. reported its second-quarter loss grew to $142.6 million, or a loss of $1.04 per share, from a loss of $126.7 million, or a loss of $1.20 per share a year earlier.In the latest quarter, the company reported a 55 cent charge per share for revaluation of warrants, compared with a similar charge of $1 in the second quarter of 2009.The Seattle biotech (NASDAQ: DNDN), which is developing the prostate cancer drug Provenge, reported revenues grew to $2.8 million from $25,000 in 2009. Anal...Read article
DENDREON CORP Files SEC form 8-K, Results of Operations and Financial Condition
2010-08-04 07:42:48
Quote: Results of Operations and Financial Condition.
On August 3, 2010, Dendreon Corporation, a Delaware corporation ("Dendreon")
issued a press release regarding Dendreon's financial results for its quarter
ended June 30, 2010. The full text of Dendreon's press release is attached
hereto as Exhibit 99.1.
The information in this report, including the exhibit, is provided under Item
2.02 of Form 8-K and, pursuant to General Instruction B.2 of Form 8-K, shall not
be deemed "filed"...Read article
Dendreon: Provenge Sales $2.8 Million
2010-08-04 07:42:48
Keywords: Financial, News, Stock, Market, Headlines, Investments, Quotes, Trading, TheStreet.com, Adam Feuerstein ,Drugs
Quote: Updated with stock price, conference call comments.TheStreet) --DendreonDNDN) reported second quarter Provenge sales of $2.8 million, the first financial measure of the prostate cancer therapy's commercial launch since it gained U.S. approval in late April.On average, analysts were expecting Provenge revenue of about $4 million in the quarter, so the prostate cancer therapy's performance fell short of consensus. The black-or-white, win-or-lose nature of Wall Street earnings reports all but requi...Read article
For Dendreon, It's 500 Prescriptions for Provenge and Counting
2010-08-04 07:42:47
Quote: By Ron Winslow
Nearly every day seems like a new milestone for Dendreon and its controversial prostate cancer treatment Provenge.
New England Journal of Medicine published the results of ImpactFDA to approve Provenge in late April. NEJM publication, the company hopes, will establish credibility for the treatment, a therapeutic vaccine that enlists a patient’s own cells to arm the body’s immune system against cancer.
as Dow Jones Newswires reports, it fell short of Wall Street’s exp...Read article